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Abstract
Objective
To clinically, genetically, and radiologically characterize a large cohort of SPG7 patients.
Methods
We used data from next-generation sequencing panels for ataxias and hereditary spastic
paraplegia to identify a characteristic phenotype that helped direct genetic testing for variations
in SPG7. We analyzed MRI. We reviewed all published SPG7 mutations for correlations.
Results
We identiﬁed 42 cases with biallelic SPG7mutations, including 7 novelmutations, including a large
multi-exon deletion, representing one of the largest cohorts so far described. We identiﬁed
a characteristic phenotype comprising cerebellar ataxia with prominent cerebellar dysarthria, mild
lower limb spasticity, and a waddling gait, predominantly from a cohort of idiopathic ataxia. We
report a rare brain MRI ﬁnding of dentate nucleus hyperintensity on T2 sequences with SPG7
mutations. We conﬁrm that the c.1529C>T allele is frequently present in patients with long-
standing British ancestry. Based on the ﬁndings of the present study and existing literature, we
conﬁrm that patients with homozygous mutations involving the M41 peptidase domain of SPG7
have a younger age at onset compared to individuals with mutations elsewhere in the gene (14
years diﬀerence, p < 0.034), whereas c.1529C>T compound heterozygous mutations are associ-
ated with a younger age at onset compared to homozygous cases (5.4 years diﬀerence, p < 0.022).
Conclusions
Mutant SPG7 is common in sporadic ataxia. In patients with British ancestry, c.1529C>T allele
represents the most frequent mutation. SPG7 mutations can be clinically predicted by the
characteristic hybrid spastic-ataxic phenotype described above, along with T2 hyperintensity of
the dentate nucleus on MRI.
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Hereditary spastic paraplegia (HSP) and hereditary cerebellar
ataxias (HCA) are heterogeneous groups of progressive
neurodegenerative conditions with considerable overlap.1,2
HSP is complicated when features such as ataxia, neuropathy,
optic atrophy, and weakness are present.3 HCA can also be
associated with spastic paraplegia. There are over 80 diﬀerent
genetic loci associated with HSP and similar number associ-
ated with cerebellar ataxias.4–6 This extensive genetic het-
erogeneity together with the overlapping features of HCA and
complicated HSP often causes diﬃculties in disease classiﬁ-
cation and clinical approach to genetic diagnosis.
Next-generation sequencing (NGS) gene panels are available
for both HSP andHCA patients. However, such panel tests are
expensive and not always readily available. Our objective was to
describe clinical, genetic, and radiologic features of a British
cohort of SPG7 cases where the phenotype may be helpful in
providing guidance to targeted genetic testing.We highlight the
importance of such clinical characterization through our ex-
perience of diagnosing a large cohort of patients withmutations
in the SPG7 gene, implicated in both HSP and HCA.7 In
addition, by reviewing all published SPG7 mutation data, we
make important new genotype-phenotype correlations.
Methods
Patient cohorts
We studied all cases positive for SPG7 mutation in our HSP
and ataxia cohorts, which mainly include patients from the
North of England (cohort study) and analyzed all clinical,
genetic, and neuroimaging data.
Standard protocol approvals, registrations
Patient consent was obtained for genetic testing in accordance
with the departmental regulations. Healthy control cases for
MRI were recruited as per ethics committee approval (REC
reference 09/H1310/79, IRAS 26259). STROBE checklist
for cohort study adhered in reporting the data.
Genetic testing
Libraries of sheared genomic DNA corresponding to panels of
either HCA or HSP genes captured using a SureSelect XT
custom designed probe set (Agilent, Cheadle, UK), and pair-
end sequenced using a HiSeq 2500 instrument (Illumina) was
used. Raw data were analyzed using the Genome Analysis
ToolKit,8 (Broad Institute, Cambridge, MA) according to
guidelines.9,10 After initial identiﬁcation of 11 patients with
SPG7 mutations using the ataxia and HSP gene panels, we
evaluated the phenotype to identify a triad of spastic paraplegia
(usually mild), cerebellar ataxia (with prominent cerebellar
dysarthria), and waddling gait indicative of proximal muscle
weakness. Thereafter, the majority of patients who presented
who had the above triad were analyzed by bidirectional Sanger
sequencing and dosage analysis (multiplex ligation-dependent
probe ampliﬁcation kit P213-B1 and B2, MRC-Holland) of all
17 exons of the SPG7 gene. The remainder of the cohort were
identiﬁed using eitherHSP orHCAgene panel testing as before.
Chromatographs were analyzed using Mutation surveyor
v4.0.8 (softgenetics.com). Annotation of mutations was car-
ried out in accordance withHumanGenome Variation society
nomenclature (hgvs.org/mutnomen), with nomenclature based
on the reference sequence NM_003119.3. Novel variants in the
SPG7 gene were assessed for pathogenicity using Alamut Visual
version 2.9.0 (Interactive Biosoftware, Rouen, France) and
prediction software (Provean, MutPred, SNPS & GO and
PolyPhen2). Allele frequencies for novel variants in normal
control populations were obtained from the Genome Ag-
gregation Database (gnomAD).11
Neuroimaging
MRIs, available for all patients who underwent MRI, were
analyzed for cerebellar atrophy. Further subanalysis of the
dentate nucleus was undertaken for all patients who un-
derwent brain imaging on the same 3-TMR scanner (Ingenia,
Philips Medical Systems, Eindhoven, The Netherlands) using
the same T2-weighted sequence (avoid machine-related var-
iability) (cases: n = 21 and controls: n = 16). This was com-
pared with age- and sex-matched controls imaged with this
sequence. The axial T2-weighted parameters were as follows:
repetition time 3,000 ms, time to echo 80, echo train length 15,
number of averages was 1 and 4 mm thick, 512 × 512 matrix.
Matching criteria for healthy controls were age within 3 years
and sex. Relative signal intensity of the dentate nucleus was
compared to normal-appearing pontine white matter and red
nucleus. A region of interest (area 20 mm2) in these structures
was placed in the region of the dentate nucleus with the lowest
signal. The dentate nucleus signal was then dichotomized
by whether the ratio of the signals was less than or more
than 1 (i.e., hypointense or hyperintense compared to normal-
appearing white matter in the pons).
Literature review
Two clinicians independently reviewed clinical and genetic
details of all SPG7 cases thus far reported in the literature
(until September 30, 2017). We searched the following terms
in PubMed, MEDLINE, Web of Science, and Embase: SPG7,
paraplegin, hereditary spastic paraparesis, HSP (mutations),
spastic ataxia, and ataxia, and selected all the articles reporting
SPG7 and/or paraplegin mutations and reviewed the pheno-
type and genotype data published. We excluded publications
that were not in English or where English translation was not
Glossary
DN = dentate nuclei; HCA = hereditary cerebellar ataxias; HSP = hereditary spastic paraplegia; NGS = Next-generation
sequencing; PEO = Progressive external ophthalmoplegia; RN = red nuclei; SARA = Scale for the assessment and rating of ataxia.
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available and articles that did not describe clinical features. All
mutations described by us and previously reported are depicted
in a schematic diagram in relation to functionally important
domains (ﬁgure 1) (e-table 1, links.lww.com/NXG/A89).
Statistical analyses
Statistical analysis was performed using Prism GraphPad
V7.0b and SPSS (2015) statistical software programs. One-
way analysis of variance was used for multiple group com-
parisons, and independent samples t test and χ2 test were used
to compare 2 groups.
Data availability
All anonymized data can be shared on a collaborative basis.
Results
Characterization of the phenotype
We identiﬁed a total of 42 cases positive for pathogenic muta-
tions in both alleles of the SPG7 gene (table 1). Initially, 11
cases were identiﬁed using ataxia or HSP NGS gene panels (4
patients using ataxia panel and 7 patients using the HSP panel).
On reviewing the phenotype of these 11 cases, we noted that 9
individuals had cerebellar ataxia with prominent slurring of
speech, mild spasticity, and proximal muscle weakness resulting
in a waddling gait.
Direct genetic screening based on
the phenotype
Following the clinical characterization of the initial 11 patients,
we undertook direct testing for mutations in the SPG7 gene in
patients who demonstrated the above phenotype in a cohort of
patients attending the Sheﬃeld Ataxia Centre and HSP clinics.
We identiﬁed a further 27 cases with pathogenic mutations
(table 1). Four other cases were already diagnosed when re-
ferred to us (panel tests).
The clinical characteristics of the 42 probands are summarized
in table 2. There was no history of consanguinity. Eighty-three
percent were male. The average age of symptom onset was
41.7 years (SD: ± 11, median age 44 years). Female patients
developed symptoms on average 4 years earlier than male
patients (38.5 vs 42.5 years) (table 2). The mean duration of
disease at the time of diagnosis was 9.6 years (SD: ±5.2, mode
5). Thirty-eight of 42 patients (90%) were of long-standing
British ancestry. Four were UK citizens of Indian, Iranian,
German, and Bulgarian descent.
Ninety-eight percent of cases presented with gait unsteadiness
followed by dysarthric speech (76%). Thirty-two patients
(76%) complained of mild spasticity. Two patients presented
with the typical spastic gait characteristic of HSP (5%) and 7
patients (16%) presented with moderate-to-severe spasticity.
Seventy-six percent (32 of 42) had mildly increased lower
limb tone and 93% had brisk reﬂexes, while the Babinski sign
was positive in 51%.
At baseline, 38 patients (90%) were found to have at least
some evidence of cerebellar ataxia and 33 (79%) were found
to have both mild spasticity and cerebellar ataxia. Despite the
cerebellar features, only 2 cases were nonambulant, with a total
symptomatic disease duration of 399 patient-years. None of the
Figure 1 Schematic diagram of the SPG7 protein with important functional domains and positioning of mutations in the
Sheffield cohort and all the published pathogenic mutations in the SPG7 gene
Mutations described in our cohort of patients are annotated above the SPG7 protein structure, while previously published mutations are below. Allelic
frequency is noted within parenthesis. New mutations detected in our cohort are highlighted in red font. Variations denoted in blue are matching com-
plementary DNA sequence of the reported mutations. Some large exon deletions reported are indicated in the text box. Parentheses from mutations
removed to create space. AAA = ATPases associated with diverse cellular activities; Coil1 and Coil2 = coiled domain; FtsH = filamentation temperature-
sensitive mutant in Escherichia coli domain; TM1 and TM2 = transmembrane domain 1 and 2. Reference sequence: NM_003119.3.
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Table 1 SPG7 gene mutations and clinical features
Pedigree Gender
Onset
age
Disease
duration
Direct/
panel
test
Presenting
phenotype
Mutation in cDNA1
reference sequence: NM_
003119.3
Predicted protein change (in
bold are new mutations
detected)
Cerebellar Spasticity
Prox.
weakness Dysarthria PEO
Optic
atrophy
Bladder
disturbanceAllele 1 Allele 2 Allele 1 Allele 2
1 M 45 5 Direct CA with spasticity,
waddling gait
c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + + + ? − − +
2 M 44 5 Ataxia CA with spasticity,
waddling gait
c.1529C>T c.1937-2A>G p.(Ala510Val) p.? + + + + − − +
3 M 30 10 HSP CA with spasticity,
waddling gait
c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + ++ + − − − +
4 M 40 6 Direct CA with spasticity,
waddling gait
c.1529C>T c.1454_
1462del
p.(Ala510Val) p.(Arg485_
Glu487 del)
+ ++ + + − − +
5 M 50 6 HSP CA with spasticity,
waddling gait
c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + + + + − − −
6 M 56 5 HSP HSP—complicated c.1529C>T c.1045 G>A p.(Ala510Val) p.(Gly349Ser) + +++ − + − − −
7 M 15 14 Direct CA with spasticity c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + +++ + + − − −
8 M 60 5 HSP HSP—pure c.1529C>T c.1045 G>A p.(Ala510Val) p.(Gly349Ser) − +++ − − − − +
9 F 24 9 Ataxia CA with spasticity c.1529C>T c.1904C>T p.(Ala510Val) p.(Ser635Leu) ? + − + − − −
10 M 51 5 Direct CA with spasticity c.1529C>T c.1454_
1462del
p.(Ala510Val) p.(Arg485_
Glu487del)
+ + − + − − −
11 M 35 6 Direct CA with spasticity,
waddling gait
c.1529C>T c.1192C>T p.(Ala510Val) p.(Arg398*) + + + − − − +
12 M 30 6 Direct CA with spasticity c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + + − + − − +
13 M 44 6 Direct CA with spasticity,
waddling gait
c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + + + ? − − ?
14 M 37 18 Direct CA with spasticity,
waddling gait
c.233T>A c.233T>A p.(Leu78*) p.(Leu78*) + + + + − + +
15 M 37 8 Direct CA with spasticity c.1529C>T c.861+2dupT p.(Ala510Val) p.(Asn288*) + + − + − − −
16 M 46 5 Direct CA with spasticity,
waddling gait
c.1529C>T c.1715C>T p.(Ala510Val) p.(Ala572Val) + + + + − − −
17 M 57 4 Direct HSP—complicated c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + + − + − − ?
18 M 29 10 Direct CA with spasticity,
waddling gait
c.1529C>T c.1192C>T p.(Ala510Val) p.(Arg398*) + ++ + + − − +
19 M 48 6 Direct HSP—complicated c.1529C>T c.1045 G>A p.(Ala510Val) p.(Gly349Ser) + + − + − − −
20 M 44 10 Direct HSP—complicated c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + + − + − − −
Continued
4
N
e
u
ro
lo
g
y:G
e
n
e
tics
|
V
o
lu
m
e
4
,N
u
m
b
e
r
6
|
D
e
ce
m
b
e
r
2
0
1
8
N
e
u
ro
lo
g
y.o
rg
/N
G
Table 1 SPG7 gene mutations and clinical features (continued)
Pedigree Gender
Onset
age
Disease
duration
Direct/
panel
test
Presenting
phenotype
Mutation in cDNA1
reference sequence: NM_
003119.3
Predicted protein change (in
bold are new mutations
detected)
Cerebellar Spasticity
Prox.
weakness Dysarthria PEO
Optic
atrophy
Bladder
disturbanceAllele 1 Allele 2 Allele 1 Allele 2
21 F 35 10 Direct CA with spasticity,
waddling gait
c.1529C>T c.1672A > T p.(Ala510Val) p.(Lys558*) + + + − − − +
22 M 55 12 HSP HSP—pure c.1529C>T c.775_
781dup
p.(Ala510Val) p.(Thr261 fs) − +++ − − − +
23 M 50 7 Direct CA with spasticity,
waddling gait
c.1529C>T c.1053dupC p.(Ala510Val) p.(Gly352 fs) + + + + − − −
24 F 48 20 Direct CA with spasticity,
waddling gait
c.1529C>T c.861+2dupT p.(Ala510Val) p.(Asn288*) + + + + − − +
25 M 31 10 Direct CA with spasticity,
waddling gait
c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + + + + − − ?
26 M 34 10 Direct CA with spasticity,
waddling gait
c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) ? N + + − − −
27 M 48 7 Direct CA with spasticity,
waddling gait
c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + + + + − − +
28 M 36 5 Ataxia CA c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + N + + − − +
29 F 15 20 Direct CA with spasticity,
waddling gait
c.1529C>T c.1904C>T p.(Ala510Val) p.(Ser635Leu) + N + + − − +
30 F 45 8 Ataxia CA c.233T>A c.233T>A p.(Leu78*) p.(Leu78*) + + + + − − +
31 M 30 20 HSP HSP—complicated c.1529C>T c.1045 G>A p.(Ala510Val) p.(Gly349Ser) + + + + − − +
32 M 46 6 HSP HSP—complicated c.1181T>C c.1045 G>A p.(Phe394Ser p.(Gly349Ser) + + + + − − +
33 M 55 7 Direct CA with spasticity,
waddling gait
c.1529C>T c.2096dup p.(Ala510Val) p.(Met699 fs) + + + − − − −
34 M 42 5 Direct CA with spasticity c.1529C>T c.1529C>T p.(Ala510Val) p.(Ala510Val) + + ? + − − ?
35 M 46 3 Direct CA with spasticity,
waddling gait
c.1529C>T del (exon
4–-9)
p.(Ala510Val) p.? + + + + + − ?
36 F 58 20 Ataxia CA c.1529C>T c.2083C>G p.(Ala510Val) p.(Leu695Val) + N − + − − −
37 M 40 12 Direct CA with spasticity,
waddling gait
c.1529C>T c.754 G>T p.(Ala510Val) p.(Gly252*) + + + + − − +
38 M 43 16 Direct CA with spasticity and
waddling gait
c.233T>A c.233T>A p.(Leu78*) p.(Leu78*) + + + − − − +
39 M 44 10 HSP HSP—complicated,
ataxia waddling
c.1529C>T c.1454_
1462del
p.(Ala510Val) p.(Arg485_
Glu487del)
+ ++ ++ − − − −
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patients could run, and 78% of the cases were using walking aid.
The severity of the ataxia was less (median scale for the as-
sessment and rating of ataxia [SARA] score 8, range: 3.5–13.5)
when compared to spino cerebellar ataxia 6 (median score
15.0) for the same duration of symptoms.
Sixty-four percent of cases demonstrated the triad of cere-
bellar ataxia with dysarthria, spasticity, and waddling gait at
presentation, and 9 others developed the full clinical picture
during follow-up (totaling 87%). Progressive external oph-
thalmoplegia (PEO) was observed only in 1 patient. Another
patient had vertical gaze palsy. Nystagmus was present in 38%
of patients. Optic atrophy was seen in 1 patient. Waddling gait
was seen in 87% of our cases.
Although 4 patients were found to have reduced vibration
sense and 3 had reduced pinprick sensation on clinical ex-
amination, none of the 19 patients who underwent neuro-
physiologic assessment had evidence of large ﬁber peripheral
neuropathy or myopathy.
Mutation analysis
Fifteen cases (36%) were homozygous for mutations in the
SPG7 gene, while 27 cases (64%) were compound hetero-
zygous. Twelve of the 15 homozygous cases had the common
missense mutation in exon 11, c.1529C>T, p.(Ala510Val),
while the other 3 cases were homozygous for the c.233T>A,
p.(Leu78*) nonsense mutation. Ninety percent of our cases
that carried the common mutation p.(Ala510Val) in at least
one allele were of British ancestry. The 3 patients homozy-
gous for the p. (Leu78*) nonsense mutation were second-
generation British citizens of Indian, Iranian, or Bulgarian
descent. The fourth case, of German descent, was compound
heterozygous for the c.1181T>C, p.(Phe394Ser) and c.1045
G>A, p.(Gly349Ser) mutations.
The frequency of the c.1529C>T, p.(Ala510Val) mutation in
our cohort was 60% (50 of 84 alleles assessed). The second
most commonmutant allele, c.233T>A, p.(Leu78*), was seen
in 3 patients in the homozygous state, while c.1045 G>A,
p.(Gly349Ser) was seen in 5 cases in a compound hetero-
zygous state. p.(Ala510Val) and p.Arg485_Glu487del muta-
tions were observed in two-thirds of the disease alleles (50
of 84). In addition, to the single case with a large deletion,
several small insertions, duplications, deletions, and splice
site mutations were detected on 7 alleles, 5 of which have
been previously described. Most of the pathogenic alleles
were missense mutations (63 of 84) while 21 were nonsense
mutations (table 1).
Novel mutations in SPG7
We discovered 7 novel likely pathogenic mutations in the
SPG7 gene (table 1), of which 5 were null mutations, with 2
frame-shift mutations c.775_781dup p.(Thr261 fs) and
c.2096dup p.(Met699 fs), 2 nonsense mutations c.754G>T,
p.(Gly252*) and c.300T>A, p.(Tyr100*), and a large de-
letion encompassing at least exons 4 to 9 (c.377−?_1324+?Ta
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del) was identiﬁed using multiplex ligation-dependent probe
ampliﬁcation. One of the novel missense mutation, c.1373C>T,
p.(Ala458Val), results in substitution of a conserved amino acid,
which is proven to be deleterious using in silico analysis while
found in one allele in gnomAD database supporting patho-
genicity. The second missense mutation c.2083C>G,
p.(Leu695Val) resulted in substitution of the same amino
acid as a previously reported pathogenic mutation c.2084T>C,
p.(Leu695Pro).12 Predictions by PROVEAN (deleterious),
PolyPhen2 (probably damaging), and MutPred (actionable
Table 2 Phenotypic description of the patients with SPG7
mutations
Features Index cases (%)
Male:female ratio 35:7
Mean age at onset (SD), y 41.7 (±11)
Mean age at onset for males (SD), y 46.6 (±10)
Mean age at onset for females (SD), y 38.5 (±15)
Mean disease duration at examination (range), y 9.2 (3–20)
Symptoms at presentation
Impaired balance 41/42 (98%)
Slurred speech 32/42 (76%)
Stiffness 32/42 (76%)
Leg weakness 10/42 (24%)
Other symptoms at presentation
Cognitive disturbance 5/42 (12%)
Deafness 1/42 (2.5%)
Bladder disturbance 22/42 (50%)
Muscle weakness 19/42 (48%)
Cranial nerve examination
Nystagmus 15/42 (38%)
Vertical gaze palsy 1/42 (2.4%)
Horizontal gaze palsy and limited vertical gaze 1/42 (2.4%)
Optic atrophy 1/42 (2.4%)
Cerebellar signs 38/42 (90%)
Dysdiadochokinesia 16/35 (48%)
Finger-nose test impaired 13/35 (39%)
Heel-shin test impaired 24/35 (67%)
Cerebellar dysarthria 32/42 (76%)
Pure spastic gait 2/42 (5%)
Muscle tone
Upper limbs
Normal 27/42 (63%)
Increased tone 5/34 (15%)
Lower limbs
Normal or reduced 3/42 (7%)
Increased tone 39/42 (93%)
Power
Upper limbs
Normal 33/36 (92%)
Reduced 3/36 (8%)
Table 2 Phenotypic description of the patients with SPG7
mutations (continued)
Features Index cases (%)
Lower limbs
Normal 33/42 (79%)
Reduced 13/42 (21%)
Sensation
Vibration
Normal 31/40 (78%)
Reduced 9/40 (22%)
Pin-prick
Normal 32/35 (91%)
Reduced 3/35 (9%)
Joint position sense
Normal 35/35 (100%)
Reduced 0/33 (0%)
Tendon reflexes
Upper and lower limbs
Normal or reduced 3/42 (7%)
Brisk 39/42 (93%)
Babinski
Positive 20/39 (51%)
Negative 19/39 (49%)
Gait
Spastic ataxia 33/42 (79%)
Pure cerebellar gait 5/42 (12%)
Spastic waddling gait 4/42 (10%)
MRI brain
Cerebellar atrophy 38/40 (95%)
Mild or no atrophy of the vermis 37/38 (98%)
Mild or no atrophy of the cerebellar hemispheres 26/38 (71%)
Severe atrophy 0/38 (0%)
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hypothesis) suggested likely pathogenicity, but this was not
supported by SNPS & GO (neutral). This allele is present in
the East Asian gnomAD normal control population at a fre-
quency of 0.4626%.
MRI brain
MRI brain imaging was available in 40 cases. Cerebellar atrophy
was noted in 95%, mostly mild atrophy of the vermis (table 2;
ﬁgure 2, A and B). T1 sequences of both dentate nuclei (DN)
and the red nuclei (RN) were not distinguishable between
controls and SPG7 cases (ﬁgure 2, A and C). The same T2
sequence on 3-T imaging was available in 21 patients and these
were matched with 17 healthy controls. In the 16 healthy con-
trols, the DN were hypointense compared to normal-appearing
white matter (ﬁgure 2C), and 1 healthy control had DN iso-
intense relative to normal-appearing whitematter. TheDNwere
isointense or hyperintense compared with normal-appearing
white matter (T2 imaging) in 18 of the 21 SPG7-positive cases
(ﬁgure 2D). Both controls and patients showed no diﬀerence in
the appearance of the RN, which were hypointense compared to
normal-appearing white matter in the pons (ﬁgure 2E). The
increase in DN T2 hyperintensity on MRI in SPG7 cases was
signiﬁcant compared to the controls (χ2 test value 25.76, at p <
0.001) (ﬁgure 2F).
Genotype-phenotype correlation
from current and other studies
We analyzed mutations in the diﬀerent functionally important
domains of SPG7 shown in ﬁgure 1 for any impact on age at
onset of symptoms. Patients who had homozygous mutation in
the M41 peptidase domain had an earlier onset of disease
symptoms (by 12 years) compared to patients with mutations
in a nonfunctionally assigned domain (p < 0.022) (ﬁgure 3A).
Having homozygous, compound heterozygous mutations
or the presence of null alleles did not have an impact on age
at onset. However, we also noted that patients with the
c.1529C>T mutation when in a compound-heterozygote state
developed symptoms 8 years earlier compared to c.1529C>T
homozygous cases (p < 0.019, unpaired t test) (ﬁgure 3B).
Discussion
We describe a large British cohort of 42 unrelated and pre-
viously unreported cases with mutations in the SPG7 gene.
The largest other single-center cohort so far reported is
a Dutch cohort of 46 unrelated families.13 We propose that
the phenotype of cerebellar ataxia (with marked dysarthria),
mild lower limb spasticity, and waddling gait is clinically
distinct and should alert clinicians to direct genetic testing
for SPG7. Such an approach identiﬁed 64% of our cohort.
While SPG7 biallelic mutations have historically been asso-
ciated with HSP, it is now clear that ataxia is the major
clinical presentation, as only 26% of our cohort presented
with an HSP-like phenotype.7,14,15 In another UK-based
study, SPG7 accounted for 18.6% of 70 patients with un-
explained ataxia and pyramidal signs.7 SPG7 is the fourth
commonest cause of any genetic ataxia in the United
Kingdom and the second commonest recessive ataxia.16 In
support of this ﬁnding, 90% of our SPG7 cohort demonstrated
gait ataxia with cerebellar dysarthria (table 2).
Only 2 patients were wheelchair-dependent, indicating that
ambulatory loss appears to be rare in SPG7 cases,15 with an
average SARA score of 8 (range: 3.5–14). This favorable
prognostic factor will be useful when counseling SPG7
patients and their families.
A considerable proportion of our cohort was male (83%). Fe-
male patients tended to develop symptoms about 4 years earlier.
The median age at onset of symptoms was 44 years, indicating
that SPG7-related disease is a late-onset disease in keeping with
previous reports.13,17 The age at onset, however, did range be-
tween 15 and 60 years; therefore, SPG7 can rarely present with
an early-onset ataxia. The recessive inheritance accounts for the
lack of a positive family history. Absence of a family history
should therefore not deter clinicians from SPG7 testing.
PEO was only seen in one of our patients but has been
reported in 11% of SPG7 cases worldwide. A previous report
found that 13% of the patients with PEO have SPG7. PEOwas
also reported in 1 of 5 cases in a UK cohort of complex HSP.18
Overall, PEO in SPG7was also rare in other cohorts, including
a French (2/23),19 a Dutch (2/46),13 and a French Canadian
cohort (none of the 22 individuals).15 A longitudinal study of
SPG7 patients from the United Kingdom reported a median
follow-up duration of 23 years from presentation to detecting
PEO,7 as did a Norwegian group (median follow-up of 24
years).20 Clinicians should be aware that PEO-like features in
SPG7 are rare but can develop late in the disease process.
Optic neuropathy was reported in 9.5% of the worldwide
SPG7 cases, compared to one patient in our cohort. In
a French cohort of SPG7 patients, 44% had evidence of optic
neuropathy based on optical coherence tomography, yet 40%
of the patients with optic neuropathy had normal-appearing
optic discs on funduscopy. It is therefore likely that optic
atrophy is common in SPG7-mutated patients but the clinical
signiﬁcance of this remains unclear.
SPG7 cases have mild cerebellar atrophy and none had severe
atrophy (table 2). The increased T2 signal from the dentate
nucleus in SPG7 cases compared to controls has not been
previously reported. The dentate nucleus is a site of iron
accumulation in normal aging, and this is usually associated
with reduced T2 signal. The high signal noted in SPG7 cases
does not appear to be due to a globally reduced brain iron
accumulation. In support of theMRI ﬁndings are postmortem
data from an SPG7 case, which showed neuronal loss in the
dentate nucleus.21 While the above imaging ﬁnding is not
speciﬁc for SPG7 mutations, yet it is an important charac-
teristic and merits further consideration.22 We propose that
dentate nucleus hyperintensity on MRI T2 sequences, with-
out severe overlying cerebellar atrophy and in the context of
a typical phenotype, aid the diagnosis of mutant SPG7.
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We also discovered 8 cases heterozygous for SPG7 (SPG7-
Het) (50% were c.1529C>T). As the pathogenicity of the
SPG7-Het is not well established, we have not included fur-
ther analysis. However, analysis of the MRI appearances
showed 2 of 8 SPG7-Hets had T2 hyperintensity of the DN
(e-table 2, links.lww.com/NXG/A90).
The association of waddling gait has not been previously
highlighted in relation to SPG7. There are a number of reports
describing muscle weakness over and above the mild pyramidal
weakness seen in patients with HSP.19 In keeping with our
observations, myopathic features were noted in a PEO co-
hort.17 Furthermore, two-thirds of the SPG7 cases from the
Dutch cohort were noted to have lower limb muscle weak-
ness.13 This weakness may account for the rationale of per-
forming muscle biopsies in some cases that have, on occasions,
shown evidence of mitochondrial dysfunction.14,19,23,24
More than 242 cases of SPG7 have been described worldwide.
Analysis of the mutations demonstrates unique genotype-
Figure 2MRI of the brain in SPG7 cases shows T2 hyperintensity of the dentate nucleus
(A) T1 axial image across the dentate nucleus (DN)
of a control case. (B) T1 axial section through the
DN in a patient with c.1529C>T homozygous
mutation. (C) T2-weighted axial image of the
same control and (D) T2 axial section through DN
in the same patient with c.1529C>T homozygous
mutation, which demonstrates hyperintense DN
(solid white arrow) compared to the normal-
appearing white matter. (E) T2-weighted axial
image of the same patient, which demonstrates
the red nucleus (RN). The RN appears hypo-
intense compared to normal-appearing white
matter in all SPG7 and control cases (solid black
arrow with white border). (F) The observation of
hyperintense T2 signal of the DNwas significantly
more frequent in the SPG7 patients compared to
the control cases (p < 0.001, χ2 test value 25.7649).
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phenotype correlations in SPG7, whereinmutations in theM41
peptidase domain are associated with younger age at onset and
c.1529C>T homozygous mutations tend to associate with later
onset of disease compared to compound heterozygotes. Fur-
ther studies are needed to conﬁrm above ﬁndings.
We identiﬁed 7 novel mutations, 70% resulting in premature
truncation of the paraplegin protein. The c.1529C>T mu-
tation was present in at least one allele in all patients with
British ancestry, strongly supporting a previous report of
its association with patients with British heritage.14 We ob-
served that c.1529C>T is the commonest mutant SPG7 al-
lele worldwide, and this allele frequency in our cohort was
60%. The c.1454_1462del mutation is the second most
common mutation (9%).
We have highlighted that SPG7 is a common cause of sporadic
ataxia. We recommend direct genetic testing for SPG7
mutations when cerebellar ataxia with dysarthria is associated
with mild lower limb spasticity and a waddling gait. If the
patient is of long-standing British ancestry, directly testing for
the c.1529C>T mutation is highly likely to be diagnostic. The
MRI feature of relative T2 hyperintensity of the DN is also
strongly supportive of mutant SPG7.
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